PharMerica's (PMC) "Outperform" Rating Reaffirmed at Barrington Research

PharMerica's (PMC) "Outperform" Rating Reaffirmed at Barrington Research


's stock had its "outperform" rating restated by equities researchers at Barrington Research in a research note issued to investors on Tuesday. They presently have a $34.00 target price on the stock, up from their previous target price of $30.00.



from Biotech News